Eli Lilly (Mexico) Insiders
| LLY Stock | MXN 13,339 869.50 6.97% |
Eli Lilly employs about 47 people. The company is managed by 47 executives with a total tenure of roughly 442 years, averaging almost 9.0 years of service per executive, having 1.0 employees per reported executive. Break down of Eli Lilly's management performance can provide insight into the company performance.
| John Lechleiter Chairman Chairman, CEO and Pres |
| Joshua Smiley President CFO, Senior Vice President |
Eli |
Eli Lilly Management Team Effectiveness
The company has return on total asset (ROA) of 0.1148 % which means that it generated a profit of $0.1148 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.6464 %, meaning that it generated $0.6464 on every $100 dollars invested by stockholders. Eli Lilly's management efficiency ratios could be used to measure how well Eli Lilly manages its routine affairs as well as how well it operates its assets and liabilities.Eli Lilly Workforce Comparison
Eli Lilly and is rated fourth overall in number of employees category among related companies. The total workforce of Drug Manufacturers - Major industry is now estimated at about 9,847. Eli Lilly adds roughly 47.0 in number of employees claiming only tiny portion of equities under Drug Manufacturers - Major industry.
The company has Profit Margin (PM) of 0.22 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.29 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.29. Eli Lilly Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Eli Lilly Price Series Summation is a cross summation of Eli Lilly price series and its benchmark/peer.
Eli Lilly Notable Stakeholders
An Eli Lilly stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Eli Lilly often face trade-offs trying to please all of them. Eli Lilly's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Eli Lilly's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| John Lechleiter | Chairman, CEO and Pres | Profile | |
| Joshua Smiley | CFO, Senior Vice President | Profile | |
| Fionnuala Walsh | Senior Vice President - Global Quality | Profile | |
| Johna Norton | Senior Vice President - Global Quality | Profile | |
| Alfonso Zulueta | Senior Vice President and President - Emerging Markets business | Profile | |
| Jeffrey Simmons | Senior Vice President and President - Elanco Animal Health | Profile | |
| Anne White | Senior Vice President and Presidentident - Lilly Oncology | Profile | |
| Leigh Pusey | Senior Vice President - Corporate Affairs and Communications | Profile | |
| Melissa Barnes | Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer | Profile | |
| Darren Carroll | Senior Vice President - Corporate Business Development | Profile | |
| Christi Shaw | Senior Vice President and President - Lilly Bio-Medicines | Profile | |
| Barton Peterson | Senior Vice President - Corporate Affairs and Communications | Profile | |
| Enrique Conterno | Sr. VP and President of Lilly Diabetes | Profile | |
| Maria Crowe | President - Manufacturing Operations | Profile | |
| Myles ONeill | Senior Vice President and President - Manufacturing Operations | Profile | |
| David Ricks | Senior Vice President and Presidentident - Lilly Bio-Medicines | Profile | |
| Daniel Skovronsky | Senior Vice President - Science and Technology, and President Lilly Research Laboratories | Profile | |
| Jan Lundberg | Executive VP of Science and Technology and President of Lilly Research Laboratories | Profile | |
| Aarti Shah | Senior Vice President - Information Technology, and CIO | Profile | |
| Susan Mahony | Senior Vice President and President - Lilly Oncology | Profile | |
| Stephen Fry | Senior Vice President - Human Resources and Diversity | Profile | |
| Derica Rice | CFO, Executive VP of Global Services, Member of Operations Committee and Member of Policy and Strategy Committee | Profile | |
| Michael Harrington | General Counsel and Sr. VP | Profile | |
| Ellen Marram | Lead Independent Director | Profile | |
| Kathi Seifert | Independent Director | Profile | |
| Ralph Alvarez | Independent Director | Profile | |
| Jamere Jackson | Independent Director | Profile | |
| Juan Luciano | Director | Profile | |
| Karen Horn | Independent Director | Profile | |
| William Kaelin | Director | Profile | |
| Karen Walker | Director | Profile | |
| Raul Alvarez | Independent Director | Profile | |
| Marschall Runge | Director | Profile | |
| David Hoover | Independent Director | Profile | |
| Carolyn Bertozzi | Independent Director | Profile | |
| Erik Fyrwald | Independent Director | Profile | |
| Jackson Tai | Director | Profile | |
| Michael Eskew | Independent Director | Profile | |
| Katherine Baicker | Independent Director | Profile | |
| Franklyn Prendergast | Independent Director | Profile | |
| Alonzo Weems | VP Officer | Profile | |
| Anat Ashkenazi | VP CFO | Profile | |
| Jacob Naarden | CEO VP | Profile | |
| Anat JD | Gen VP | Profile | |
| Diogo Rau | VP Officer | Profile | |
| Donald Zakrowski | Chief Fin | Profile | |
| Martin MIBS | VP Projects | Profile |
About Eli Lilly Management Performance
The success or failure of an entity such as Eli Lilly often depends on how effective the management is. Eli Lilly management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Eli management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Eli management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. ELI LILLY operates under Drug Manufacturers - Major classification in Mexico and is traded on Mexico Stock Exchange. It employs 33610 people.
The data published in Eli Lilly's official financial statements usually reflect Eli Lilly's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Eli Lilly. For example, before you start analyzing numbers published by Eli accountants, it's critical to develop an understanding of what Eli Lilly's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Eli Lilly's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Eli Lilly's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Eli Lilly's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Eli Lilly and. Please utilize our Beneish M Score to check the likelihood of Eli Lilly's management manipulating its earnings.
Eli Lilly Workforce Analysis
Traditionally, organizations such as Eli Lilly use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Eli Lilly within its industry.Eli Lilly Manpower Efficiency
Return on Eli Lilly Manpower
| Revenue Per Employee | 607.3M | |
| Revenue Per Executive | 607.3M | |
| Net Income Per Employee | 132.9M | |
| Net Income Per Executive | 132.9M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly and. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Complementary Tools for Eli Stock analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Transaction History View history of all your transactions and understand their impact on performance |